Apremilast in Combination With Clobetasol Spray for the Treatment of Plaque Psoriasis

Part of paid clinical trials in Rockville, Maryland.

Sponsor
Washington Dermatology Center
Study ID
NCT03453190
Phase
PHASE4
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Apremilast and Clobetasol — COMBINATION_PRODUCT
    Patients will receive apremilast and clobetasol with tapering dosages over 16 weeks.

Study Details

Researchers want to find out if giving the drug Apremilast in combination with Clobetasol spray can help people clear their moderate to severe plaque psoriasis quicker than if Apremilast is used by itself.

Key Dates

First listed
Mar 5, 2018
Start date
Feb 25, 2018
Status verified
Feb 2018
Primary completion
Mar 1, 2020
Completion
Jun 30, 2020

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: Psoriasis Patients on Comb. Treatment
    Patients will be given Apremilast 30 mg bid and Clobetasol Spray 0.05 % bid on a tapering schedule over 16 weeks.

Primary Outcome Measure

Psoriasis Area Severity Index (PASI) [ Time Frame: 16 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Washington Dermatology CenterRockvilleMaryland20852
Vicki Smith
[email protected]
301-984-3000
Ronald Prussick, M.D.
[email protected]
3019843000
Ronald Prussick, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Rockville, MD

By condition
Psoriasis
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
Washington Dermatology Center· Rockville, MD

Related Studies